首页> 外文期刊>International Journal of Pharmaceutical Sciences and Research >DRUG USE EVALUATION OF SHENMAI INJECTION IN THE FIRST AFFILIATED HOSPITAL OF BENGBU MEDICAL COLLEGE: A PROSPECTIVE ANALYSIS
【24h】

DRUG USE EVALUATION OF SHENMAI INJECTION IN THE FIRST AFFILIATED HOSPITAL OF BENGBU MEDICAL COLLEGE: A PROSPECTIVE ANALYSIS

机译:蚌埠医学院第一附属医院参麦注射液药物利用评价:前景分析。

获取原文
       

摘要

Introduction: To investigate the evaluation pattern of Traditional Chinese medicine injection, establish the drug use evaluation(DUE) standards of shenmai injection, and implement of DUE programs of shenmai injection in the First Affiliated Hospital of Bengbu Medical College. Methods: Three hundred and thirty four patients were included in this retrospective analysis. The study duration was divided into two periods: cycle A: from November 2011 to December 2011; cycle B: from January 2012 to March 2012. A series of indices including indications, administration frequency, dosage, administration period, drug-drug interactions, adverse reactions and treatment efficiency were evaluated. Results: The number of patients showed the indications of shenmai injection were 119 (77.27%) and 168 (93.33%) in cycle A and cycle B, respectively. The number of patients showed the contraindications of shenmai injection were 18 (11.69%) and 12 (6.67%) in cycle A and cycle B, respectively. Satisfactory outcomes were reported among all the patients with no serious adverse reactions reported. Conclusions: The establishing of the standards of Traditional Chinese medicine injection should integrate the guidelines approved by drug use evaluation system. There are some shortcomings for the evaluation of Traditional Chinese medicine injections. The drug use evaluation of shenmai injection could promote the reasonable application of the injection in clinical practices.
机译:简介:为了探讨中药注射剂的评价模式,建立了参麦注射剂的药物使用评价(DUE)标准,并在蚌埠医学院第一附属医院实施了参麦注射剂的DUE计划。方法:本回顾性分析纳入了344例患者。研究持续时间分为两个阶段:周期A:从2011年11月至2011年12月;周期B:从2012年1月至2012年3月。评估了一系列指标,包括适应症,给药频率,剂量,给药时间,药物-药物相互作用,不良反应和治疗效率。结果:在A周期和B周期中,参麦注射液的适应症分别为119例(77.27%)和168例(93.33%)。在A周期和B周期中,参麦注射液的禁忌症分别为18例(11.69%)和12例(6.67%)。在所有患者中均报告了满意的结果,未报告严重不良反应。结论:中药注射剂标准的制定应结合用药评价体系认可的指导原则。中药注射剂评价存在一些不足。参麦注射液的用药评价可以促进其在临床实践中的合理应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号